Context: Treatment with growth hormone (GH) is considered effective in improving adult height (AH) in Turner syndrome (TS). However, there are few studies comparing AH between treated patients and a concurrent untreated group. Objective: To assess the efficacy of GH treatment in improving AH in TS and to review previous published studies with treated and untreated groups. Participants and Methods: We retrospectively analyzed clinical data and AH of a large cohort of GH-treated (n = 168) and untreated (n = 131) patients with TS. Data are shown as median and interquartile range (IQR). We assessed pretreatment variables related with AH and compared our results with 16 studies that also included an untreated group. Results: The GH-treated group was 6.2 cm taller than the untreated group (AH = 149 cm [IQR 144.5–152.5 cm] vs. 142.8 cm [IQR 139–148 cm], p #x3c; 0.001) after 4.9 years of GH treatment with a dose of 0.35 mg/kg/week. AH SDS corrected for target height (TH) was 7.2 cm higher in GH-treated patients. AH SDS ≥−2 was more frequent in GH-treated patients (43%) than in untreated patients (16%, p #x3c; 0.001). AH SDS was also more frequently within the TH range in the GH-treated group (52%) than in the untreated group (15%, p #x3c; 0.001). Height SDS at start of GH therapy and TH SDS were positively correlated with AH (p #x3c; 0.001; R² = 0.375). Considering the current result together with previous similar publications, a mean AH gain of 5.7 cm was observed in GH-treated (n = 696) versus untreated (n = 633) patients. Conclusions: Our study strengthens the evidence for efficacy of GH therapy in patients with TS from different populations.
Horm Res Paediatr

中文翻译：

---

使用或不使用生长激素治疗的 299 名特纳综合征患者的成人身高：结果和文献回顾

背景：生长激素 (GH) 治疗被认为可有效改善特纳综合征 (TS) 的成年身高 (AH)。然而，很少有研究比较治疗患者和同期未治疗组之间的 AH。目的：评估 GH 治疗在改善 TS 中 AH 的功效，并回顾以前发表的对治疗组和未治疗组的研究。参与者和方法：我们回顾性分析了大量接受 GH 治疗（ n = 168）和未接受治疗（ n = 131）的 TS 患者的临床数据和 AH。数据显示为中位数和四分位距 (IQR)。我们评估了与 AH 相关的治疗前变量，并将我们的结果与 16 项研究进行了比较，其中还包括未治疗组。结果： GH治疗组比未治疗组高 6.2 cm（AH = 149 cm [IQR 144.5–152.5 cm] vs. 142.8 cm [IQR 139–148 cm]， p #x3c；0.001）在 GH 治疗 4.9 年后剂量为 0.35 mg/kg/周。在接受 GH 治疗的患者中，根据目标身高 (TH) 校正的 AH SDS 高 7.2 厘米。AH SDS ≥-2 在接受 GH 治疗的患者 (43%) 中比未接受治疗的患者 (16%, p #x3c; 0.001)更常见。AH SDS 在 GH 治疗组 (52%) 中的 TH 范围内的频率也高于未治疗组 (15%, p #x3c; 0.001)。GH 治疗开始时的身高 SDS 和 TH SDS 与 AH 呈正相关（ p #x3c；0.001； R ²= 0.375）。考虑到当前的结果以及之前的类似出版物，在接受 GH 治疗的 ( n = 696) 与未接受治疗的 ( n = 633) 患者中，观察到的平均 AH 增加了 5.7 cm 。结论：我们的研究加强了 GH 治疗对来自不同人群的 TS 患者的疗效的证据。
儿科研究